Answers are grounded in this paper and cite their sources.
Analytical review identifies genetic markers influencing angiogenesis and extracellular matrix in cardiovascular disease treatment.
Traditional methods of treatment and prevention of cardiovascular disease (CVD) are not always effective, especially in severe myocardial injury. One of the promising areas for the treatment of cardiac pathologies is cell transplantation using tissue-engineered constructs from allogeneic stem cells, such as cell sheets. The success of cell therapy depends on the severity of local inflammatory reactions, angiogenesis activity, resistance of transplant cells to hypoxia and apoptosis, as well as on their production of extracellular matrix. Single nucleotide polymorphisms (SNPs) in genes involved in the processes associated with CDV can serve as markers of genetic dysfunction of these genes in the cardiovascular system and be used to predict the efficacy of the heart disease therapy based on tissue-engineered constructs. The review systematizes the information, allowing us to form a panel of such SNPs and analyze it. We identified seven genes at the intersection of pathways that are key to the survival of cellular constructs, VEGFA, TGFBI, FN1, IL6R, ITIH4, NRP1 and CDHI3, and selected SNPs rs998584, rs8108632, rs1250259, rs6689306, rs77347777, rs75082222 and rs6565060, which are located in the regions of these genes and associated with CVD according to the Genome-Wide Association Study (GWAS). These polymorphisms may constitute a minimal panel to search for an association with the efficacy of cell therapy in heart disease.
No takes yet. Share an insight, caveat, or question.
I. S. Kiselev (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: